Personalized cancer vaccines are a powerful tool for boosting the immune system’s response to cancer cells. Such patient-individualized vaccines require an in-depth understanding of all mutations of the tumor and the body’s MHC types. CeGaT’s CancerNeo® provides the insights required for the design of vaccines: The analysis of a patient’s tumor exome data detects tumor-specific mutations and predicts neoepitopes, which are important targets for tumor elimination. The expression of these neoantigens is confirmed by whole RNA sequencing (transcriptome) from the same FFPE tissue.
Neoepitopes are abnormal peptides, which are little fragments of proteins. Body cells constantly present peptides on their surface, indicating the current state of the cell. Immune cells can recognize if a cell presents normal peptides or abnormal ones and use this information to determine and eliminate defective cells. Neoepitopes are also produced by tumor mutations and represent targets for tumor elimination. To strengthen the neoepitope recognition through vaccination hence supports cancer treatment.
Treating physicians receive two comprehensive medical reports. One report highlights the treatment options based on variants identified in cancer-relevant genes. The second report gives a selection of neoantigens that can be used to create a personalized vaccination.
- Processing time: 4-6 weeks after sample receipt
- Highest confidentiality and quality standards
- Our customer service accompanies you at each single step